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A synthetic gene coding for the cysteine proteinase inhibitor (desSerl I e29 Leu89) chicken cystatin was cloned and ex- 
pressed in E. coll. The gene was assembled from 12 oligonucleotides and inserted into vector pUC 8. Expression as fusion 
protein was performed ina temperature-inducible E. coli system. The expression product was synthesized as 20% of total 
E. coli protein. The fusion protein was purified, the chicken cystatin homologue was spht off with CNBr and the N- 
terminal sequence confirmed up to position 37. The properties of the purified material correspond to those of natural 
chicken cystatin. The recombinant cystatin variant binds anti-chicken cystatin IgG, is inhihitorily active and displays 
K~ values with papain and with cathepsin B similar to those determined for natural chicken cystatin. 
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1. INTRODUCTION 
Chicken cystatin of  Mr 13000 is one of  the best 
investigated tight binding inhibitors of  cysteine 
proteinases [1]. It was or iginal ly isolated f rom egg 
white [2]; later on two forms of  dif ferent p I  and 
t runcated forms were character ized [3-5].  The 
dissociat ion constants of  their papain  complexes 
were measured ([6] Machleidt ,  W.  et al., submit-  
ted). The amino acid sequence o f  one form was 
determined [3,7], and Gly9 A la l0  were suggested 
to represent the putat ive reactive site residues [8]. 
Very recently the X-ray crystal structure of  chicken 
cystat in was solved and the possible mode of  in- 
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teract ion with papain elucidated [9]. The detai led 
knowledge of  its structure and binding mode as 
well as the expected therapeutic potential  o f  cys- 
teine proteinase inhibitors made a recombinant  
product ion  of  this interesting molecule very attrac- 
tive. Therefore a synthetic master gene was design- 
ed, synthesized, cloned, expressed and the puri f ied 
product  biochemical ly characterized. 
2. MATERIALS  AND METHODS 
2.1. Oligonucleotide synthesis and fragment assembly 
The 12 oligonucleotides were synthesized by thephosphite 
triester method [10] using the phoshoramidite chemistry [11] on
a Pharmacia gene assembler. The material was purified by 
denaturing polyacrylamide gel lectrophoresis. The hybridisa- 
tion of oligonucleotides (100 pmol each) and their ligation i to 
segments A and B is outlined in fig. 1 and was performed as 
described elsewhere [12,13]. 
2.2. Construction of cloning and expression vectors 
Segments A and B were purified on 2% agarose gels after 
cleavage with PstI and ligated into pUC 8 vectors cut with 
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EcoRI/Pstl and Pstl/HindlII, respectively (molar atio of vec- 
tor:fragment, 1:5). Transformed E. coli RRI delta M15 cells 
[14] were selected after plasmid preparation [15], restriction 
analysis and DNA sequence analysis [16]. The complete gene 
was constructed by isolating segment A from pGG 1.6.1 and 
ligating it into the EcoRI/PstI cleaved vector pGG 5.1.2 har- 
bouring segment B. Out of several transformants a construct 
with the correct DNA sequence of the (desSerl Ile29 Leu89) 
chicken cystatin gene was selected (pGG 8.1.1). The gene incor- 
porated in an EcoRI/BamHI fragment was purified and ligated 
into expression vector pEx 3 lb [17]. As expression host we used 
E. coli CGSC 6769 (Central Genetic Stock Center, Yale) which 
was transformed with pcI 857 to provide the system with the 
heat labile repressor cI 857, which is necessary forheat induc- 
tion [18]. Analysis of the correct insertion was done by direct 
screening for fusion proteins after induction of the E. coli cells 
[131. 
2.3. Expression and isolation of the chicken cystatin 
homologue 
The expression of the fusion protein, its isolation and the 
CNBr cleavage of the fusion protein were performed as de- 
scribed elsewhere [13,19], with modifications for heat induction 
(1 h, 42°C and 3 h, 32°C). The reaction mixture containing the 
uncleaved fusion protein, the chicken cystatin homologue, the 
fusion protein part of MS-2 pol and the acidolytic fragment of 
the MS-2 pol part (resulting from the cleavage of the acid sen- 
sitive Asp-Pro bond) were fractionated by gel filtration on 
Sephadex G-50 and these fractions were analysed separately. 
2.4. Biochemical and immunological haracterization 
Natural chicken cystatin was prepared as described [20]. This 
material was used to prepare antibodies in rabbits [21]. From 
antisera, IgGs were immunoselected by affinity chromatogra- 
phy [22]. For SDS-PAGE [23], Western blot analysis [24,25] 
and amino acid sequencing [26] recombinant and natural 
material were used. For detection of inhibitory activity purified 
fusion protein and ( esSerl I1e29 Leu89) chicken cystatin were 
refolded uring stepwise dilution from 6 M to 2 M urea fol- 
lowed by passage through a small Sephadex G-25 column 
(NAP-10, Pharmacia) equilibrated with the assay buffer [13]. 
Fluorometric assays were used for titrations with papain and 
cathepsin B. The K~ estimations with papain (EC 3.4.22.2, type 
III, Sigma, repurified by covalent chromatography on mer- 
curial agarose [27]) and with human cathepsin B (EC 3.4.22.1; 
kindly provided by T. Popovic) were done as described 
elsewhere [13,28,29]. Natural highly purified chicken cystatin 
used as reference was only the long form of the inhibitor ([5] 
Machleidt, W. et al., submitted). 
3. RESULTS 
3.1. Design, gene assembly and cloning 
A synthetic gene coding for a homologue of  
chicken cystatin was designed on the basis of  its 
amino acid sequence [3,7] and its ut i l izat ion as 
recombinant  gene product  for protein engineering. 
The structure o f  the gene and the strategy of  syn- 
thesis are out l ined in fig.1. The ol igonucleot ide 
bui ld ing blocks with the codon usage for highly ex- 
pressed proteins in E. coli were chosen [30]. 
Unique cleavage sites were selected by help o f  the 
UWGCG sequence analysis software [31]. The 
strategy for cloning and expression of  the gene in- 
c luded the incorporat ion of  an EcoRI site, an ATG 
start codon at the 5 ' -end ,  two stop codons as well 
as a BamHI and a HindIII site at the 3 ' -end.  The 
internal  Met residues at posit ions 29 and 89 were 
subst ituted by Ile and Leu, respectively, to al low 
the release of  an intact inhibitor by CNBr  cleavage 
after the ATG coded Met residue l inking the MS-2 
pol  part  with the inhibitor.  The fol lowing residue, 
Ser l ,  the first amino acid o f  the natural  inhibitor 
was deleted because it is known that Met-Ser pep- 
t ide bonds are cleaved poor ly  by CNBr  [32]. The 
subst itut ions hould alter neither structure nor  
funct ion because both methionines are replaced in 
some of  the related cystatins by Ile29 and by Leu89 
[1]. The first amino acid of  chicken cystatin, Ser l ,  
is assumed not  to be structural ly or funct ional ly 
impor tant  [9]. Based on experience obta ined in 
construct ion o f  genes for aprot in in  and stefin B 
[12,13], the gene was assembled in a modular  way 
as shown in figs 1 and 2. Both puri f ied segments A
and B were cloned separately into vector pUC 8; 
among several t ransformants  the vectors pGG 
1.6.1 and pGG 5.1.2 were selected after DNA se- 
quencing. The correct f ragments were used for 
construct ion o f  pGG 8.1.1 harbour ing the com- 
plete gene. Addi t iona l  t ransformants  containing 
certain deletions were found and will be described 
elsewhere. 
3.2. Expression o f  (desSerl I1e29 Leu89) chicken 
cystatin 
For  expression of  the chicken cystatin 
homologue gene a temperature inducible E. coli 
expression system with the vectors pEx 3 lb ,  pci857 
and E. coli strain CGSC 6769 was chosen 
[13,17,19]. Af ter  induct ion and analysis o f  total  E. 
coli proteins by SDS-PAGE the resulting E. coli 
strain 1083 was selected, expressing the fusion o f  
MS-2 po l -ch icken  cystatin homologue.  The  main 
prote in band migrat ing at an Mr o f  24000 cor- 
responds to 25°7o of  total  E. coli proteins (fig.3). 
The fusion protein aggregated as inclusion bodies 
and was immunologica l ly  detected after Western 
blott ing with ant ibodies against native chicken 
cystat in (fig.3). 
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Fig. 1. (A) Design of the synthetic chicken cystatin homologue gene. The boxed amino acids are believed to be part of structurally 
important sites. (B) DNA and amino acid sequences of (desSerl Ile29 Leu89) chicken cystatin. 
3.3. Isolation and characterization 
From 3.5 1 fermentation broth (10 g E. coli wet 
wt) about 1.5 g inclusion bodies (wet wt) were 
isolated and purified by gel filtration under reduc- 
ing (10 mM ~-mercaptoethanol) and denaturing 
conditions (6 M urea) on a Sephacryl S-300 col- 
umn (about 200 mg). After CNBr cleavage the 
fragments: MS-2 pol fusion protein of 216 aa, 
chicken cystatin homologue of 115 aa, MS-2 pol of 
101 aa and the acidolytic MS-2 pol fragment of 66 
aa (resulting from the cleavage of the acid labile 
Asp35-Pro36 bond) were detected (fig.3) and 
separated on a Sephadex G-50 column. Fractions 
containing essentially pure (desSerl Iie29 Leu89) 
chicken cystatin, contaminated with minor 
amounts of fusion protein, were isolated (fig.3). 
The material was used for amino acid sequencing, 
Western blotting (fig.3) and inhibition studies 
(table 1). The N-terminal amino acid sequence was 
confirmed up to position 37 including Ile29 
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substituted for Met (table 1). Contamination with 
MS-2 pol was less than 3%. The substituted amino 
acid residue Leu89 was identified in the expected 
position by sequencing unseparated tryptic 
fragments that had been selectively immobilized 
via their lysyl side chains ([26], not shown). After 
partial refolding by passage through a Sephadex 
G-25 column 37o70 of the fusion protein and 40O7o 
of (desSerl I1e29 Leu89) chicken cystatin quan- 
titated by Azso determination were found to be in- 
hibitorily active by titration with papain (table 2). 
The estimated Ki values for the inhibition of pa- 
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(1 b 
Fig.3. Electrophoretic analysis b  (a)SDS-PAGE (5-2007o) and by (b) Western blot with immunoprint. (A) Low molecular mass 
standards; (B) E. coli lysate with pEx 31b (4 x 108 cells); (C) E. coil lysate with pGG 9.1.1 (4 x 108 cells); (D) cleavage products after 
CNBr treatment (about 1 mg wet wt); (E) (desSerl Ile29 Leu89) chicken cystatin after gel filtration (20/,1 sample, A2s0 = 0.9) and 
(F) natural chicken cystatin (20/~1 sample, A28o = 0.9). 
pain and human cathepsin B are very similar to 
those obtained with natural chicken cystatin. 
These assays were done in parallel for natural and 
recombinant material: the values closely resemble 
those reported previously [1]. No significant dif- 
ferences were found between the inhibition con- 
stants of (desSerl Ile29 Leu89) chicken cystatin 
and of the fusion protein (table 2). 
4. DISCUSSION 
We have cloned a synthetic gene of chicken 
cystatin and expressed it in E. coli, as a fusion pro- 
tein together with 101 amino acids of MS-2 pol. 
We have further shown that modified (desSerl 
I1e29 Leu89) chicken cystatin can be recovered 
from the recombinant fusion protein after cleavage 
with CNBr in a biologically active form. Within 
the expected limits of error, the Ki values for the 
inhibition of papain and human cathepsin B are 
identical with those of the natural inhibitor. With 
the isolation procedure described here about 5 mg 
of pure inhibitor was obtained per litre E. coli 
broth. Scaling-up and improvement of isolation 
should further increase the yield. The selected ap- 
proach enables us to produce variants which ac- 
cording to the X-ray crystal structure and the 
suggested binding mode [9] might be critical either 
for the structure of this molecule or for effective 
binding to cysteine proteinases. These variants will 
further be used to study the refolding pathway and 
the significance of various structural components 
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Table 1 
N-terminal amino acid sequence of (desSerl 
chicken cystatin 
I1e29 Leu89) 
Step Residue Yield a Step Residue Yield a 
(nmol) (nmol) 
1 X b 20 Leu 0.90 
2 Asp 3.02 21 Gin 0.45 
3 Arg 1.90 22 Arg 0.59 
4 Ser 0.54 23 Ala 0.53 
5 Arg 0.84 24 Leu 0.67 
6 Leu 1.15 25 Gln 0.31 
7 Leu 1.33 26 Phe 0.39 
8 Gly 0.65 27 Ala 0.41 
9 Ala 0.97 28 Ile 0.39 
10 Pro 0.54 29 Ala 0.45 
II Val 1.19 30 Glu 0.17 
12 Pro 0.39 31 Tyr 0.32 
13 Val 0.95 32 Asn 0.24 
14 Asp 0.68 33 Arg 0.40 
15 Glu 0.51 34 Ala 0.30 
16 Asn 0.59 35 Ser 0.16 
17 Asp 0.77 36 Asn 0.27 
18 Glu 0.50 37 Asp 0.28 
19 Gly 0.29 
a Raw yields of amino acid phenylthiohydantoin derivatives as 
determined by on-line HPLC without correction for 
background and overlap 
b Due to the applied method [26], the N-terminal residue is 
bound to the sequencing support and was not identified 
Table 2 
Inhibitory activity of the fusion protein and of (desSerl I1e29 
Leu89) chicken cystatin 
(desSerl Ile29 Leu89 
Natural Chicken Fusion 
chicken cystatin protein 
cystatin 
Inhibitory 
activity a 62°7o 40o70 37% 
Ki (nM) with 
Papain 0.007 0.005 b 0.008 0.007 
Cathepsin B 3.9 1.7 b 5.7 5.6 
a Calculated from the inhibitorily active concentration 
determined by titration with papain and the protein 
concentration measured by A2s0 
b Data from [1] 
for stability and to clarify the interaction 
mechanism. 
Only very recently cysteine proteinase inhibitor 
genes were produced by recombinant DNA 
methods, namely human cystatin C [33,34], stefin 
A [35], rat cystatin alpha [36] and stefin B [13,37]. 
These recombinant inhibitors will facilitate the 
elucidation of reaction mechanisms, of structure 
and function relationship and encourage studies on 
therapeutic effectiveness of these proteins. 
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